Paragon Therapeutics
Tracked across 9 events · 368 articles · First seen Jul 21, 2025 · Last active Aug 23, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Paragon Therapeutics is facing a class action lawsuit for allegedly providing misleading statements regarding its lead cell therapy candidate drug, deramiocel, which led to a significant stock price decline after the United States — Food and Drug Administration denied its Biologics License Application.
Jul 21, 2025 · 31 articles
Regulatory
Impact: Paragon Therapeutics announced that the Cellular, Tissue, and Gene Therapies Advisory Committee of the United States — Food and Drug Administration will convene a meeting to discuss its Biologics License Application for Deramiocel, a cell therapy for Duchenne muscular dystrophy. This is a significant step towards potential market approval for their lead product candidate.
Jun 26, 2026 · 6 articles
Business
Impact: Divests MTX652 to focus on CNS pipeline, receives up to $292M in payments.
Jul 17, 2026 · 6 articles
Regulatory
Paragon Therapeutics, a biotechnology company developing Deramiocel for Duchenne muscular dystrophy, faced a major regulatory setback. On July 27, 2026, the FDA released briefing documents ahead of an advisory committee meeting, raising concerns about post-hoc…
Impact: Central company facing regulatory rejection and multiple securities fraud lawsuits; stock collapsed over 78%.
Jul 27, 2026 · 287 articles
Tech
Impact: Paragon Therapeutics is a spinout company co-founded by Professor Stuart Forbes to commercialize the macrophage therapy. The company is currently testing a new version of the therapy, RTX001, in the EMERALD clinical trial, indicating significant progress and potential for future market impact.
May 25, 2026 · 7 articles
Business
Impact: Paragon Therapeutics, NicOx's exclusive licensee in China, received positive pre-submission regulatory feedback for NCX 470, allowing them to proceed with the New Drug Application submission in China. This is a significant step towards commercializing the drug in their licensed territories.
Jun 18, 2026 · 7 articles
Regulatory
NicOx announced that its exclusive licensee in China, Paragon Therapeutics, has submitted a New Drug Application (NDA) to the Chinese China — National Medical Products Administration (NMPA) for NCX 470, a novel nitric oxide-donating bimatoprost…
Impact: Ocumension is the exclusive licensee in China and submitted the NDA. It has already invested €18 million in license fees and contributed to trial costs, positioning itself for a commercial launch and potential revenue from NCX 470 sales.
Aug 10, 2026 · 6 articles
Business
Impact: Altor BioScience was launched based on assets licensed from Paragon Therapeutics, indicating its foundational role in Altor BioScience' existence.
Jun 03, 2026 · 12 articles
Business
Impact: Glicko rating system was Chief Commercial Officer of Paragon Therapeutics.
Jun 09, 2026 · 6 articles
100
Paragon Therapeutics submitted NDA China — National Medical Products AdministrationNCX 470 NDA submitted in China
100
United States — Food and Drug Administration released briefing documents Paragon TherapeuticsCapricor Deramiocel FDA...
100
United States — Food and Drug Administration released briefing documents Paragon TherapeuticsCapricor Deramiocel FDA...
100
Robbins LLP filed class action Paragon TherapeuticsCapricor Deramiocel FDA...
99
Paragon Therapeutics announced advisory meeting United States — Food and Drug AdministrationCapricor Deramiocel FDA...
99
United States — Food and Drug Administration denied Biologics License Application Paragon TherapeuticsCapricor Deramiocel FDA...
99
Rosen Law Firm filed class action lawsuit Paragon TherapeuticsCapricor Deramiocel FDA...
97
Robbins Geller Rudman & Dowd LLP filed class action Paragon TherapeuticsCapricor Deramiocel FDA...
95
Paragon Therapeutics faced securities fraud lawsuitCapricor Deramiocel FDA...
95
United States — Food and Drug Administration released briefing documents Paragon TherapeuticsCapricor Deramiocel FDA...
95
Bronstein, Gewirtz & Grossman, LLC filed class action Paragon TherapeuticsCapricor Deramiocel FDA...
91
Bleichmar Fonti & Auld LLP announced investigation Paragon TherapeuticsCapricor Deramiocel FDA...
90
Schall Brown & Schwartz LLP filed class action Paragon TherapeuticsCapricor Deramiocel FDA...
90
Block & Leviton filed securities fraud lawsuit Paragon TherapeuticsCapricor Deramiocel FDA...
90
DJS Law Group filed class action Paragon TherapeuticsCapricor Deramiocel FDA...
90
Darren Ngasseu Nkamga filed lawsuit Paragon TherapeuticsCapricor Deramiocel FDA...
90
Glancy Prongay & Murray filed class action Paragon TherapeuticsCapricor Deramiocel FDA...
90
Bleichmar Fonti & Auld LLP filed class action Paragon TherapeuticsCapricor Deramiocel FDA...
89
Paragon Therapeutics issued press releaseCapricor Deramiocel FDA...
89
Paragon Therapeutics provided misleading statementsCapricor Deramiocel FDA...
89
Kaplan Fox & Kilsheimer filed class action Paragon TherapeuticsCapricor Deramiocel FDA...
88
Paragon Therapeutics stock droppedCapricor Deramiocel FDA...
87
Hagens Berman filed class action lawsuit Paragon TherapeuticsCapricor Deramiocel FDA...
85
Paragon Therapeutics faced multiple investigationsCapricor Deramiocel FDA...
85
Paragon Therapeutics announced positive trial resultsCapricor Deramiocel FDA...
85
Paragon Therapeutics faced multiple investigationsCapricor Deramiocel FDA...
85
Kahn Swick & Foti filed class action lawsuit Paragon TherapeuticsCapricor Deramiocel FDA...
80
Paragon Therapeutics paid license fees NicOxNCX 470 NDA submitted in China
80
The Law Offices of Frank R. Cruz announced investigation Paragon TherapeuticsCapricor Deramiocel FDA...
80
Levi & Korsinsky commenced investigation Paragon TherapeuticsCapricor Deramiocel FDA...
+ 14 more actions
View on Dashboard
ERGEN INTELLIGENCE
Track Paragon Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard